Alexander Thompson

Derek Archila

Emily Bodnar

Gospel Enyindah-Asonye

Liam Hiester

Samuel Slutsky

- Appili Therapeutics Inc. and its partner Vitalex Biosciences were awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) for up to **US$40 million** to develop **VXV-01**, a vaccine against invasive fungal infections.  **[1851194_eecf1e0d5b7b4f7e812fea90cb634b3e_0]** 
- The **five-year** contract includes a **22-month base period** of **US$3.6 million** and **twelve additional option periods** valued at approximately **US$36.3 million**.  **[1851194_eecf1e0d5b7b4f7e812fea90cb634b3e_0]** 
- This funding is expected to support the development of **VXV-01** through Investigational New Drug (IND) submission and completion of **Phase 1 clinical trials**.  **[1851194_eecf1e0d5b7b4f7e812fea90cb634b3e_0]** 
- Appili Therapeutics has also submitted additional U.S. government funding proposals for other infectious disease products, with a combined potential award value of up to **US$97 million**.  **[1851194_eecf1e0d5b7b4f7e812fea90cb634b3e_0]** **[1851194_eecf1e0d5b7b4f7e812fea90cb634b3e_1]**

Ventyx Biosciences (VTYX)